The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells
Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses challenges with developing efficacious CAR-T cell products for the treatment of patients with acute myeloid leukemia (AML), highlighting the heterogeneity of this disease. Dr Haubner then shares some insights into the development of IF-BETTER-gated CAR-T cells, which have demonstrated promising pre-clinical activity and will soon be evaluated in a first-in-human trial. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda Pharmaceuticals: Research support
